KTTAW — Pasithea Therapeutics Corp. Warrant

Pasithea Therapeutics Corp. Warrant (KTTAW) is a biotechnology company listed on NASDAQ. It is led by Tiago Reis Marques M.D., Ph.D., based in 1111 Lincoln Road, Miami Beach, FL, United States, 33139, with about 4 employees. Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Net income was -$3.0M.

Use this KTTAW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KTTAW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KTTAW SEC filings page. Lician reads the product cache first so this HTML stays unique to Pasithea Therapeutics Corp. Warrant even when a live quote feed is slow.